New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
12:41 EDTACT, JNJ, TEVA, ENDPChicago files lawsuit against Actavis, Endo, Janssen, Teva, Chicago Tribune says
Chicago has filed a lawsuit against Actavis (ACT), Endo Health Solutions (ENDP), Teva's (TEVA) Cephalon, Johnson & Johnson's (JNJ) Janssen Pharmaceuticals and Purdue Pharma, accusing the companies of concealing the risks associated with certain painkillers, the Chicago Tribune reports. The suit alleges the companies used "deceptive marketing practices to encourage doctors to prescribe and patients" to purchase more of these painkillers, leading to a rise in the "misuse and abuse" in the drugs. Reference Link
News For ACT;JNJ;TEVA;ENDP From The Last 14 Days
Check below for free stories on ACT;JNJ;TEVA;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 17, 2014
08:44 EDTENDPBioDelivery Sciences remains takeout candidate for Endo, says Summer Street
Summer Street believes a potential takeover of BioDelivery Sciences (BDSI) by partner Endo (ENDP) is no less likely after Endo made a bid to acquire Auxilium (AUXL). The firm believes an Endo buyout of BioDelivery is likely a 2015 event when BioDelivery's Bunavail for opioid dependence is on the market and BEMA Buprenorphine is facing FDA approval. Summer Street says it is a buyer of BioDelivery Sciences on weakness this morning and keeps a Buy rating on the name with a $28 price target.
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information
08:06 EDTENDPAuxilium likely to require higher bid from Endo, says MKM Partners
After Endo (ENDP) made a $28.10 per share bid for Auxilium (AUXL), MKM Partners believes that Endo will probably have to bid at least $32 to buy Auxilium. The firm raised its price target on Auxilium to $32 from $26 and reiterates a Buy rating.
08:05 EDTTEVAEagle Pharm says Teva requests motion to dismiss Bendamustine lawsuit
Subscribe for More Information
07:58 EDTENDPEndo, Auxilium deal can create significant synergies, says Canaccord
Subscribe for More Information
07:39 EDTENDPEndo deal for Auxilium highly complimentary, says UBS
Subscribe for More Information
07:15 EDTENDPEndo bid for Auxilium positive, says Wells Fargo
Subscribe for More Information
07:14 EDTENDPAuxilium to 'carefully review' proposal from Endo for $28.10 per share
Subscribe for More Information
07:12 EDTENDPQLT Inc. provides update on merger with Auxilium
QLT Inc. (QLTI) announces that it has been advised by Auxilium Pharmaceuticals (AUXL) that Auxilium has received an unsolicited offer from Endo International (ENDP) to acquire all of the issued and outstanding shares of Auxilium. Auxilium has further advised QLT that the board of Auxilium is reviewing the Endo Proposal, and has not withdrawn, modified, withheld, changed or qualified its recommendation with respect to the proposed merger with QLT pursuant to the Agreement and Plan of Merger among QLT, Auxilium, QLT Holding, and QLT Acquisition, dated June 25. The Merger Agreement continues in full force and effect. In accordance with the Merger Agreement, QLT has consented to the adoption by Auxilium of a stockholder rights plan in response to the Endo Proposal.
07:11 EDTENDPAnalysts say Auxilium QLT deal could be snarled by Endo bid, Reuters says
Subscribe for More Information
07:04 EDTENDPAuxilium could be worth $34-$45/share in takeout, says Jefferies
Jefferies believes Auxilium (AUXL) could be worth more than the $28.10 per share offer by Endo (ENDP). The firm says it can get to valuations of $34-$45 per share for Auxilium under a takeout scenario. Jefferies thinks proposed acquisition cost "leaves considerable value on the table." It keeps a Buy rating on Auxilium with a $34 price target. In pre-open trading, Auxilium is trading well above Endo's offer price at $30.26 per share, up 41% or $8.74.
06:36 EDTENDPEndo volatility expected to move on Endo acquisition proposal
Subscribe for More Information
06:25 EDTENDPAuxilium volatility expected to move on Endo acquisition proposal
Subscribe for More Information
September 16, 2014
17:29 EDTENDPAuxilium up 42% following Endo acquisition proposal
16:48 EDTENDPEndo delivers proposal to acquire Auxilium for $28.10 per share in cash, stock
Subscribe for More Information
16:48 EDTENDPEndo delivers proposal to acquire Auxilium for $2.2B in cash, stock
Subscribe for More Information
11:51 EDTACTOECD looks to close tax loopholes with new proposals
Subscribe for More Information
07:31 EDTJNJEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
06:06 EDTACTActavis, subsidiary sued by NY attorney general, Reuters says
New York attorney general Eric Schneiderman filed a lawsuit versus Actavis and its subsidiary, Forest Laboratories, to impede the firms from stopping its Alzheimer's medication production, claiming that they were aiming to illegally maintain a monopolistic stance, according to Reuters, citing comments from Schneiderman. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use